Rtw Investments Adds $55M in Candel Therapeutics, Inc. ($CADL)

RTW Investments has taken a new position in Candel Therapeutics, Inc. (NasdaqGM: CADL), according to its latest 13F filing with the SEC. The investment firm acquired 6,422,018 shares, which are valued at around $54.97 million. This marks a significant entry for RTW Investments into the biotechnology company, which specializes in developing immunotherapies for cancer patients.

What Changed in RTW Investments' Candel Therapeutics Position

RTW Investments' move represents a new buy as the firm previously held no shares in Candel Therapeutics. The acquisition of 6,422,018 shares, valued at approximately $54.97 million, indicates a considerable investment in the company's potential. This transaction suggests confidence in Candel's ongoing development of cancer treatments.

Other Institutional Activity in Candel Therapeutics

Several other institutional investors have also been active in Candel Therapeutics. FMR LLC increased its holdings by 2,752,718 shares, bringing its total to 10,987,017 shares worth about $53.84 million. Acorn Capital Advisors, LLC added 917,431 shares, ending with 3,497,948 shares valued at approximately $17.21 million. BlackRock, Inc. expanded its position by 247,353 shares, now holding 3,109,042 shares valued at $15.23 million. Portolan Capital Management, LLC significantly boosted its stake by 1,198,958 shares, reaching a total of 2,894,325 shares valued at $14.18 million.

Candel Therapeutics Stock Snapshot

Shares of Candel Therapeutics traded near $8.56. The company has a market cap of $627.19 million, a forward P/E ratio of 38.91, and a beta of -0.482, indicating less volatility compared to the market. The stock's 52-week range is between $4.35 and $9.57, with a 50-day moving average of $7.26 and a 200-day moving average of $5.84. Candel maintains a strong liquidity position with a current ratio of 28.05 and a quick ratio of 27.63, though it has a debt-to-equity ratio of 35.70.

Insider Buying and Selling at Candel Therapeutics, Inc.

Insider activity at Candel Therapeutics has been notable, with multiple insiders purchasing shares earlier this year. On March 31, 2026, Paul Manning acquired 4,618 shares, Nicoletta Loggia bought 779 shares, and Joseph Papa purchased 2,795 shares, all at an average price of $4.11. Previously, on February 23, 2026, Paul Manning also bought 550,458 shares at $5.45. Additionally, on January 26, 2026, Chief Medical Officer William Garrett Nichols and CFO Charles Schoch bought 136,500 and 232,000 shares, respectively, at no cost.

Analysts Set New Price Targets

Several analysts have recently weighed in on Candel Therapeutics. On March 18, 2026, Citigroup maintained its buy rating with a price target of $26.00. Canaccord Genuity also maintained a buy rating with a $25.00 target on March 13, 2026. The consensus among analysts is a strong buy recommendation, with a mean price target of $20.29 based on seven opinions.

About Candel Therapeutics

Candel Therapeutics, Inc., headquartered in Needham, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing immunotherapies for cancer treatment. The company is advancing its CAN-2409 and CAN-3110 candidates through various phases of clinical trials targeting prostate cancer, non-small cell lung cancer, and recurrent high-grade glioma. Candel also utilizes its enLIGHTEN Discovery Platform to create new viral immunotherapy candidates for solid tumors.

Bottom Line

RTW Investments' new position in Candel Therapeutics underscores the interest in the company's innovative approach to cancer treatment. Investors closely monitor such filings to gauge institutional confidence. It's important to remember that 13F filings reflect past holdings and may not represent current positions.